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Drug use is much more than just a pharmacological phenomenon. The same is true for 
toxicity. Harms may often be mediated by intermediary drug-triggered behaviours through 
which the harm occurs, or even by behaviours resulting from distorted reputation of the drug. 
We need to broaden our consideration of toxicity.  
 
The purpose of this editorial is to provoke wider consideration of unintended harms of 
medications given/taken with the intention of benefitting the recipient. We propose that the 
concept of toxicity be expanded beyond simple drug-induced adverse events. We consider 
two additional forms of ‘toxicity’. Each is a ‘mediated toxicity’ in which the harm (toxicity) 
occurs via intermediate behaviour or reputational damage that are triggered by a medication. 
Both scenarios lead to the altered use of a medication to the detriment of the intended 
recipient.   
 
We are all familiar with the notion of toxicity in terms of the potential of a particular 
medication to cause harm to the recipient [1], which may occur in a dose-related or 
idiosyncratic fashion. We understand this easily when we can identify a simple cause-and-
effect relationship (drug>harm). Liver damage in paracetamol overdose or allergic reactions 
to penicillin are examples where toxicity is directly attributable to the medication. But 
sometimes there is an intermediate step (drug->behaviour->harm) or even a series of steps 
(drug->reputation->behaviour->harm). 
 
Behaviourally-mediated toxicity: In some circumstances and some patients, a medication 
may provoke atypical behaviour which then causes harm (toxicity). While the harm is not a 
direct effect of the medication, it results from the behaviour that is nevertheless triggered by 
the medication - hence ‘behaviourally-mediated’.  
 
We give three examples:  
 
(i) A patient receives disulfiram (Antabuse) treatment with limited knowledge and with 
ambivalence and engages in binge drinking in an effort to ‘drink through’ the unpleasant and 
potentially dangerous disulfiram-ethanol reaction [2].   
(ii) An excessive naloxone dose is used to reverse overdose and triggers acute opioid 
withdrawal (‘over-antagonism’). The overdose victim consequently engages in further active 
drug-seeking to end withdrawal, with risk of rebound toxicity and potentially fatal outcome 
when the effect of the short-acting naloxone wears off [3].  
(iii) A patient in a trial of cocaine vaccine reports escalation in quantity of cocaine used in 
those with higher antibody titres, who attempt to over-ride vaccines or blockade [4]. 
Technologically remarkable anti-drug vaccines and ultra-long-acting blocking drugs are 
currently in development, but we must be mindful of possible unanticipated adverse 
consequences. Could these new medications trigger use of other drugs not blocked by the 
antagonist or the vaccine, thereby provoking a potential new substance use disorder, or 
even switching to a more rapid route of administration (e.g. from snorting to injecting) to 
circumvent the blockade? We should contemplate the possibility.  
 
Reputationally-mediated toxicity: It may seem strange to include, in a consideration of 
toxicity, a medication’s reputation. However, shaped by scientific and clinical reports, 
promotion from manufacturers, media and political assertions, and street folklore, the 
reputation of a medication (good or bad) can greatly influence whether clinicians offer it to 
patients and whether patients accept, use, and adhere to a particular medication (separate 
from its actual appropriateness or otherwise). We propose the term “reputationally-mediated 
toxicity” to describe when a medication acquires a reputation that alters the medication 
usage behaviour which then causes toxicity.  
 
Examples from general medicine illustrate how the harm (toxicity) results from the behaviour 
that is triggered by the reputation of the drug - hence ‘reputationally-mediated’. The positive 
reputation attached to antibiotics led to overprescribing over a half-century, creating 
penicillin-related allergic reactions and the evolution of medication-resistant bacteria. In the 
opposite direction, the negative reputation of childhood vaccinations leads to ‘vaccine 
hesitancy’ and fewer vaccinations for fear of relatively rare adverse reactions, causing a 
resurgence of measles outbreaks and associated fatalities [5,6].  
 
For the addictions field, reputationally-mediated toxicity is an overlooked major influence on 
the extent to which valuable medicines are considered and the competence with which they 
are used. Yet we pay it no real attention.  
 
i) The reputation of naloxone among drug users in Glasgow in the late 1990s was that of a 
punishment for drug users, to be avoided at all costs [7], likely deterring help-seeking as well 
as hostility to emergency care. For widespread take-home naloxone distribution, a 
reputational turn-around of naloxone was essential for service user acceptance and for 
public preparedness to assist lay-observer administration.  
 
ii) Medications to clear chronic hepatitis C infection (thereby preventing cirrhosis or primary 
liver cancer) have produced only limited benefit, because first-generation antiviral treatments 
were unpleasant to take, required long-term treatment and were only partially effective, 
leading to frequent avoidance of treatment. New-generation Hep C treatments have much 
milder side-effects and shorter duration of treatment and produce near-universal clearance 
of the virus; but a reputation turnaround is needed if real benefit is to be achieved.  
 
iii) Methadone is one of the most extensively researched medications in medicine, but the 
influence (sometimes supporting, sometimes opposing) of public and professional reputation 
has been profound. Concerns about dependence liability sometimes deter consideration of 
Opiate Substitution Treatment [8] despite consistent evidence of reduced deaths and 
improved social functioning [9,10], and accounts that ‘methadone gets into your bones’ 
(perhaps true, who knows?) imply that, for personal safety, it should be avoided. The paper 
by Uebelacker [11] illustrates how profound the influence of beliefs (their term) can be. 
 
iv) Naltrexone powerfully blocks the effects of virtually all opiates, and may protect former 
heroin users at times of vulnerability. However some practitioners and agencies 
communicate that any pharmacological assistance is antithetical to what they consider to be 
recovery. This reputational issue can close off a potentially valuable therapeutic option 
before it is even considered. 
 
In conclusion, we want to draw attention to the fact that drug toxicity is much more than a 
pharmacological event. A drug does not act in a vacuum – patterns of use depend on user 
characteristics and social context. We understand it as having bio-psycho-social dimensions. 
We argue that the same is true for toxicity. There are pathways to adverse consequences 
that need examining if we are to understand and prevent them; behaviour and reputation are 
two examples of mediators but there are likely to be more.  
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